Sucampo, Takeda Initiate Global Pivotal Phase 3 Program of Lubiprostone in Pediatric Functional Constipation

Sucampo Pharmaceuticals (Nasdaq: SCMP ) and its development and commercialization partner Takeda Pharmaceuticals (OTC: TKPYY ) today announced the initiation of a global pivotal Phase 3 clinical program of lubiprostone in pediatric functional constipation. Functional constipation is a very common gastrointestinal complaint in children and is on the